YD Bio Limited YDES

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $596,817 · Filed Apr 30, 2026

YD Bio Limited (YDES) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $596,817 and a net loss of $8.3 million. Free cash flow was -$8.0 million. As of Dec 31, 2025 it held $6.0 million in cash and investments and $13,528 in total debt.

Revenue
$596,817
Net income
$-8.31M
Operating cash flow
$-6.60M
Free cash flow
$-8.04M
EPS
$-0.12
Dividend per share
None
Shares outstanding
70.79M
Net cash
$5.99M
FY 2025
Operating margin
-883.3%
FY 2025

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
YDES (Nasdaq), YDESW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Taipei City
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2011674
Former names
True Velocity, Inc./DE (until Jun 21, 2024)

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Revenue
$596,817
Operating income
-$5.3M
Net income
-$8.3M
Diluted EPS
-$0.12
Operating cash flow
-$6.6M
Free cash flow
-$8.0M
Total assets
$13.8M
Total liabilities
$16.6M
Stockholders' equity
-$2.9M
Cash and investments
$6.0M
Total debt
$13,528

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Sep 1, 2026 Jun 30, 2026
6-K Current report (foreign issuer) Aug 11, 2026 Aug 11, 2026
6-K Current report (foreign issuer) May 1, 2026 Apr 30, 2026
20-F Annual report (foreign issuer) Apr 30, 2026 Dec 31, 2025
6-K Current report (foreign issuer) Feb 26, 2026 Feb 26, 2026
6-K Current report (foreign issuer) Jan 30, 2026 Jan 30, 2026

All 80 YD Bio Limited SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.